We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+5.01%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$531M
AUM Growth
-$19.6M
Cap. Flow
-$36.7M
Cap. Flow %
-6.9%
Top 10 Hldgs %
30.22%
Holding
139
New
9
Increased
20
Reduced
40
Closed
15

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$8.09M
2
SYK icon
Stryker
SYK
+$5.81M
3
AMSG
Amsurg Corp
AMSG
+$5.72M
4
ABMD
Abiomed Inc
ABMD
+$5.69M
5
HOLX
Hologic
HOLX
+$5.45M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$6.82M
2
BDX icon
Becton Dickinson
BDX
+$6.76M
3
BIIB icon
Biogen
BIIB
+$5.81M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$4.91M
5
INSY
Insys Therapeutics, Inc.
INSY
+$4.49M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Financials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDT icon
1
Medtronic
MDT
$106B
$24.5M 4.61%
282,500
+6,000
+2% +$485K
SYK icon
2
Stryker
SYK
$123B
$21.2M 3.99%
177,000
+52,000
+42% +$5.81M
CELG
3
DELISTED
Celgene Corp
CELG
$19.3M 3.64%
196,050
-14,500
-7% -$1.5M
ABT icon
4
Abbott
ABT
$175B
$15M 2.82%
381,500
– –
CAH icon
5
Cardinal Health
CAH
$53.5B
$14.7M 2.77%
188,780
+29,150
+18% +$2.32M
UNH icon
6
UnitedHealth
UNH
$387B
$14M 2.64%
99,200
+6,200
+7% +$827K
BIIB icon
7
Biogen
BIIB
$30.4B
$13.2M 2.48%
54,500
-22,040
-29% -$5.81M
GILD icon
8
Gilead Sciences
GILD
$167B
$13.1M 2.46%
156,500
-76,800
-33% -$6.82M
ILMN icon
9
Illumina
ILMN
$28.2B
$12.9M 2.42%
94,139
-52
-0.1% -$7.39K
AMGN icon
10
Amgen
AMGN
$198B
$12.7M 2.39%
83,500
-19,500
-19% -$3.03M
BSX icon
11
Boston Scientific
BSX
$65.4B
$11.7M 2.2%
500,000
– –
TEVA icon
12
Teva Pharmaceuticals
TEVA
$37.3B
$11.5M 2.17%
229,190
+33,900
+17% +$1.8M
JAZZ icon
13
Jazz Pharmaceuticals
JAZZ
$15.5B
$10.6M 2%
75,300
+12,800
+20% +$1.89M
REGN icon
14
Regeneron Pharmaceuticals
REGN
$70.9B
$10.5M 1.97%
30,000
-2,400
-7% -$924K
ZBH icon
15
Zimmer Biomet
ZBH
$17.6B
$10.4M 1.95%
88,786
– –
BDX icon
16
Becton Dickinson
BDX
$43.6B
$10M 1.88%
60,475
-42,256
-41% -$6.76M
CYTO
17
DELISTED
Altamira Therapeutics Ltd
CYTO
$9.09M 1.71%
27
– –
LGND icon
18
Ligand Pharmaceuticals
LGND
$6.08B
$8.47M 1.59%
113,861
-17,312
-13% -$1.28M
CNC icon
19
Centene
CNC
$32.8B
$8.38M 1.58%
234,760
+23,000
+11% +$722K
HOLX
20
DELISTED
Hologic
HOLX
$8.24M 1.55%
238,300
+157,300
+194% +$5.45M
AGN
21
DELISTED
Allergan plc
AGN
$8.11M 1.53%
+35,100
New +$8.09M
ISRG icon
22
Intuitive Surgical
ISRG
$122B
$7.94M 1.49%
108,000
-9,000
-8% -$633K
CVS icon
23
CVS Health
CVS
$137B
$7.64M 1.44%
79,800
-6,400
-7% -$638K
BAX icon
24
Baxter International
BAX
$11.7B
$7.51M 1.41%
166,000
+36,000
+28% +$1.58M
INCY icon
25
Incyte
INCY
$23.4B
$7.28M 1.37%
91,000
– –
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2016 Portfolio in Review

As of Q2 2016, Bellevue Group held 139 positions worth $531M, down 3.6% from $551M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group withdrew a net $36.7M in Q2 2016, closing 15 positions and reducing 40 holdings. Its most notable exit was Insys Therapeutics, Inc., an estimated $4.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials.

Against the trend, Bellevue Group opened a new position in Allergan plc worth $8.11M.

  • Bellevue Group's largest Q2 2016 buy was Allergan plc: 35,100 shares worth $8.11M.
  • Bellevue Group added most to Stryker in Q2 2016, an estimated $5.81M increase.
  • Bellevue Group's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $6.82M.
  • Bellevue Group fully exited Insys Therapeutics, Inc. in Q2 2016, selling an estimated $4.49M.
  • Bellevue Group's ten largest holdings make up 30% of its $531M portfolio in Q2 2016.
  • Bellevue Group opened 9 new positions and closed 15 in Q2 2016.
  • Bellevue Group's portfolio value fell 3.6% quarter-over-quarter to $531M.

Based on Bellevue Group's 13F filing for Q2 2016, filed 12 Aug 2016.